Last reviewed · How we verify
NCT07487597
Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors
EARLY_PHASE1 trial testing Enhanced ALPP CAR-T treatment in Solid Tumor in 24 participants. Currently enrolling.
28 February 2028
Quick facts
| Lead sponsor | TCRCure Biopharma Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 28 February 2026 |
| Primary completion | 28 February 2028 |
| Estimated completion | 28 February 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- Enhanced ALPP CAR-T treatment — full drug profile →
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
Sponsor
TCRCure Biopharma Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of functionally enhanced ALPP-targeted engineered T Cells (Herein referred to as Enhanced ALPP CAR-T) in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07487597
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
- NCT07327632 — This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
Other TCRCure Biopharma Ltd. trials
Trials by the same sponsor.
- NCT07246304 — TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC · EARLY_PHASE1 · recruiting
- NCT07108140 — Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors · EARLY_PHASE1 · terminated
- NCT05357027 — HPV16 E6 TCR T Cells for Cervical Carcinoma · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07487597 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TCRCure Biopharma Ltd.
- Last refreshed: 23 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07487597.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing